News & Events

Guangzhou, China, June 4, 2026 — Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have received at least two prior systemic therapies, including BTK inhibitors.

Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations

From April 24 to 25, 2026, the Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was held in Harbin, where a series of updated CSCO clinical practice guidelines were released. Rocbrutinib, an innovative drug independently developed by Lupeng Pharmaceutical, was included in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoma for the first time, receiving a recommendation as a second-line treatment for mantle cell lymphoma (MCL). This marks a milestone for Lupeng Pharmaceutical in bringing this innovative product to truly benefit patients.

For the first time, Lupeng Pharma reported the results of the Phase I clinical study in patients with solid tumors treated with LP-118, a novel Bcl-2/Bcl-xL dual inhibitor of the company's small molecule innovative drug at the AACR Annual Meeting 2026. The phase 1 clinical study reported is the first human study of LP-118, led by Professor Wu Yilong and Professor Zhou Qing from Guangdong Provincial People's Hospital，China. The data showed that LP-118 is a novel Bcl-2/Bcl-xL dual inhibitor with favorable safety and PK profiles. Preliminary efficacy observed in patients with advanced SCLC is encouraging, supporting further clinical evaluations.

Lupeng Pharmaceutical presented the preclinical evaluation of the novel orally bioavailable MDM2-targeting PROTAC (NW-8-461) in acute leukemia and myelofibrosis, a small molecule innovative project, in form of poster at the AACR Annual Meeting 2026 (San Diego).